Intravitreal Methotrexate as a Prophylactic Strategy for Proliferative Vitreoretinopathy in High-Risk Retinal Detachment
This retrospective study of 60 eyes demonstrates that intraoperative intravitreal methotrexate infusion during pars plana vitrectomy is a safe and effective prophylactic strategy for proliferative vitreoretinopathy, achieving high single-surgery anatomical success rates—particularly in grade B cases—without causing ocular or systemic toxicity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human eye is a delicate organ, and when the retina—the light-sensitive layer at the back—peels away from its support, it is a medical emergency known as retinal detachment. If not repaired quickly, the cells that allow us to see can die, leading to permanent blindness. Surgeons can reattach the retina, but the body's own healing response sometimes works against them. Instead of settling down, the eye's internal tissues can form scar-like membranes that contract and pull the retina away again. This condition, called proliferative vitreoretinopathy, is the primary reason why retinal detachment surgeries fail. It is a stubborn problem that often requires multiple, increasingly complex operations, leaving many patients with poor vision or no vision at all.
For decades, researchers have searched for a way to stop this scarring process before it begins. One promising candidate is a medication called methotrexate, which is known to calm down the overactive cells that cause this excessive scarring. However, giving this drug to the eye is tricky; injecting it repeatedly after surgery can irritate the eye's surface, and waiting until the scarring has already started might be too late to be effective. The question remained: could a single, carefully timed dose of this drug, given right during the surgery, act as a shield to prevent the scarring from ever taking hold?
A team of surgeons at Rostock University Medical Center in Germany set out to test this idea. They focused on patients who were already at high risk for developing these scars, or who had already started to form them. In a study involving 60 eyes, the surgeons performed the standard procedure to reattach the retina, but with a crucial addition. As they worked, they flushed the inside of the eye with a saltwater solution that contained a specific amount of methotrexate. This infusion lasted for at least thirty minutes, bathing the delicate tissues in the medication while the surgeon repaired the retina, and then stopped. The goal was to interrupt the biological signals that trigger scarring at the very moment the eye was most vulnerable.
The results of this approach were encouraging, particularly for those patients who had not yet developed severe scarring. In eyes where the scarring was just beginning, the surgery succeeded in reattaching the retina with a single operation in more than ninety percent of cases. This rate was significantly lower than the recurrence rate reported in a specific historical cohort of similar cases managed without adjuvant therapy, a finding that is particularly notable because no other published series has yet treated PVR Grade B with methotrexate to allow for a direct comparison. For the patients who had more advanced scarring, the success rate was lower, but still comparable to other complex treatments, and importantly, the drug did not cause any new harm. No patients suffered from toxicity related to the medication, and their vision either improved or remained stable, depending on how much damage the detachment had caused before the surgery began.
The researchers also looked closely at how the eye functioned after the treatment. Using specialized tests that measure the electrical signals of the retina, they confirmed that the drug did not damage the healthy parts of the eye. The patients who had lost their central vision due to the detachment saw their sight improve significantly, while those who still had central vision before the surgery kept it. The study found that the type of gas or oil used to hold the retina in place after surgery mattered, with gas showing better immediate success rates in this specific group, but the use of the drug itself was safe regardless of the method used to seal the eye.
While the study was not a final proof that this method works for everyone, it provided strong evidence that it is a safe and feasible strategy. The researchers noted that the drug seemed most effective when used early, before the scar tissue had a chance to become thick and tough. Once the scarring was well-established, the drug could not easily reverse the damage, which explains why the results were better for the early-stage cases. The team concluded that this method of delivering the drug during the operation avoids the side effects of repeated injections and targets the problem at its source.
This work suggests a new way to think about preventing vision loss in complex eye surgeries. By introducing the medication directly into the surgical environment, doctors may be able to stop the eye from overreacting to the trauma of the repair itself. The study did not claim to have solved the problem of retinal detachment, but it offered a clear path forward. It showed that a standardized, one-time infusion of methotrexate is safe for patients and can lead to better outcomes, especially when the eye is caught in the early stages of the scarring process. The findings invite further research to confirm these results in larger groups, but they already offer hope that the cycle of failed surgeries and re-operations might be broken for many more patients in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.